Mar 15, 2023 / 03:20PM GMT
Mark Breidenbach - Oppenheimer & Co. Inc. - Analyst
Hi, everyone. Thanks again for joining us on day three of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the research analysts here at Oppenheimer.
Our next presenting company is ESSA Pharma, which is developing novel androgen receptor targeting therapeutics for prostate cancer. And joining us this morning, we have the company's CEO, David Parkinson; and COO, Peter Virsik. They're going to be walking us through the story. We'll try and to save a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to submit it to the website, and I'll be happy to relay your questions to management.
So with that said, let's dive right into the presentation. David, the mic is yours.
David Parkinson - ESSA Pharma Inc. - President, CEO & Director
Thank you very much, Mark, and thanks for the opportunity to speak at your meeting. Peter and I will describe ESSA today. Here are the forward-looking statements. And Peter,
ESSA Pharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers